r s s feed icon
Depression: Major Depression & Unipolar Varieties
Resources
Basic Information
Introduction and Types of DepressionRelated Disorders / ConditionsHistorical and Current UnderstandingsBiology, Psychology and SociologyTreatment - Medication and PsychotherapyAlternative Medicine and Self-Help ResourcesSpecial IssuesReferences
More InformationTestsLatest News
Young Parents May Be Especially Prone to DepressionPsychological Violence Predicts Postnatal DepressionSomatic Depression Symptoms Show Heart Risk LinkSpouse's Deployment Status Tied to Depression RiskSertraline May Not Be Effective for Depression in Heart FailureFish, Fatty Acid Intake Tied to Lower Depression Risk in BoysMany With Depression Have Periods of HypomaniaBrain Research May Help Predict Anxiety, Depression in YoungDepression Linked to Slow Healing of Diabetic Foot UlcersAntiepileptics Don't Raise Risk of Suicide in Epilepsy PatientsPathological Internet Use Linked to Teen DepressionAddictive Internet Use Tied to Depression in TeensPeople Who Are Depressed 'See' a Gray WorldMood Disorders Going Undetected in U.S. ChildrenBrain Changes in MS May Spur DepressionDepression Linked to Higher Risk of Alzheimer's, DementiaType 2 Diabetes Diagnosis May Temporarily Up Depression RiskGeneric Effexor XR ApprovedPreventive Intervention for Premature Infants EffectiveDepression Can Make Pain WorseHealth Tip: Don't Suddenly Stop AntidepressantsPost-Combat Stress Disrupting Daily Lives of Returning VetsCertain Popular Antidepressants Linked to Cataracts in SeniorsRisk of Miscarriage Linked to AntidepressantsDepression Key Consideration in Acute Coronary SyndromeAllergies Might Trigger DepressionDrug Switch Tied to Depression Remission at Six MonthsBrain Injury Patients Plagued by Poor Sleep, DepressionDepression Common at End of Terminal CancerFor Depression, Phone Therapy May Be an AnswerMajor Depression Often Follows Brain InjuryPostpartum Depression Can Strike New DadsTreatment Found to Reduce Depression in PsoriasisDepression After Heart Attack Tied to Brain ChangesOlder Adults Have Lower Rates of Mood, Anxiety DisordersNo One Antidepressant Raises Suicide Risk More Than OthersMagnetic Stimulation Found Effective for DepressionAntidepressants in Pregnancy May Impact Child BehaviorDepression Linked to Increased Chocolate ConsumptionAntidepressants May Improve Heart HealthDepression and Smoking Go Hand in Hand in U.S.Health Tip: Coping With Postpartum DepressionKids' Suicide Risk Same for All AntidepressantsMedian Duration of Bipolar I Mood Episodes Is 13 WeeksBrain Glitch May Raise Some Girls' Odds of DepressionHelp for Depressed Latinos Often Hampered by StigmaAntidepressants Effective in Physically IllOutcomes of Depression Drug Treatment Affected by DiabetesCombination Treatment May Help Depressed AlcoholicsPassive Response to Social Stress Linked to Depression
Questions and AnswersLinksBook ReviewsSelf-Help Groups
Related Topics

Anxiety Disorders
Bipolar Disorder
Suicide
Addictions: Alcohol and Substance Abuse
Pain Management

Technique Shows Potential of Bapineuzumab in Alzheimer's

HealthDay News
by -- A. Agrawal, PhD
Updated: Mar 11th 2010

 

new article illustration

THURSDAY, March 11 (HealthDay News) -- A neuroimaging technique known as carbon-11-labelled Pittsburgh compound B (11C-PiB) positron emission tomography (PET) shows that treating patients with mild to moderate Alzheimer's disease with an antibody that targets amyloid-β is associated with a 25 percent reduction in amyloid-β deposits compared with placebo, according to a study published online March 1 in The Lancet Neurology.

Juha O. Rinne, M.D., from the University of Turku in Finland, and colleagues randomly assigned 28 patients with mild to moderate Alzheimer's disease to placebo or intravenous infusions of one of three doses of bapineuzumab, a humanized anti-amyloid-β monoclonal antibody, every 13 weeks.

Using 11C-PiB PET as a marker of cortical fibrillar amyloid-β load, the researchers found that, at 78 weeks, patients taking bapineuzumab had a significant decrease in the mean 11C-PiB retention ratio, while patients on placebo had a significant increase in the mean retention ratio. The effect was similar for all three bapineuzumab doses. They estimated that bapineuzumab treatment was associated with a 25 percent reduction in cortical fibrillar amyloid-β compared with placebo. Adverse events were observed in both groups and were typically transient and mild to moderate in severity.

"Treatment with bapineuzumab for 78 weeks reduced cortical 11C-PiB retention compared with both baseline and placebo," Rinne and colleagues conclude. "11C-PiB PET seems to be useful in assessing the effects of potential Alzheimer's disease treatments on cortical fibrillar amyloid-β load in vivo."

The study was funded by Elan Pharmaceuticals and Wyeth Research. Several authors reported financial, advisory or consulting relationships with Elan and Wyeth, as well as with other pharmaceutical and biotechnology companies.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

This article: Copyright © 2010 HealthDay. All rights reserved.

JAMHI


Resources
About UsBoard Meetings ScheduleEmployment ApplicationFeedbackHelpful Telephone NumbersLinksLocationSearch EngineTests & Questionnaires


Professional Resources
Continuing EducationLicensure Information


CONTACT JAMHI

By Mail
Juneau Alliance for Mental Health, Inc.
3406 Glacier Hwy.
Juneau, AK 99801

By Phone
(907) 463-3303

By Fax
(907) 463-6858

By Email
info@jamhi.org

 

 


powered by centersite dot net

About Us | About CenterSite | Terms & Privacy
Copyright © CenterSite, LLC, 1995-2010